Mangoceuticals(US:MGRX) Globenewswire·2025-02-12 13:00Core Viewpoint - Mangoceuticals, Inc. is advancing research into respiratory illness prevention technologies, specifically targeting avian influenza viruses (H5N1) in the poultry industry [1][2]. Group 1: Research and Development - The company has partnered with Vipragen Biosciences to conduct independent efficacy studies for developing an antiviral solution for respiratory illnesses in humans, based on patented technology acquired from IntraMont Technologies [2]. - Phase I animal studies have shown significant efficacy in reducing lung viral load, and the compounds are now moving into Phase II animal studies [2][4]. - The company is also exploring a drinking water-based application for poultry, focusing on the efficacy of this solution in preventing avian flu infections [3][4]. Group 2: Market Context and Impact - The ongoing avian flu outbreak has led to the culling of over 148 million birds in the U.S. since 2022, severely impacting egg and poultry production and causing consumer prices to rise, with the national average price of eggs reaching $4.15 per dozen as of December 2024, and a forecasted 20% increase in 2025 [5][6]. - Farms are incurring significant costs on biosecurity measures to protect flocks, highlighting the need for a more effective and cost-efficient approach to disease prevention [6]. - The global poultry market is projected to reach $375.41 billion by 2030, indicating a substantial opportunity for Mangoceuticals' water-based antiviral solution if proven effective [7]. Group 3: Strategic Vision - The company aims to provide a simple, compliant, and non-pharmaceutical method to enhance immune defenses in poultry, potentially revolutionizing disease prevention in livestock and reducing financial strain on farmers [4][7]. - Mangoceuticals is committed to delivering scalable solutions that protect livestock, stabilize the food supply, and prevent future pandemics, with final study results expected upon completion [8].